Drug Fix: CAR-T Malignancy Reports, Background Music In DTC Ads, New No. 2 At US FDA

Citeline Podcasts

English - December 01, 2023 18:03 - 20 minutes - 12.3 MB - ★★★★★ - 24 ratings
Business News Business News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: RNA And Kidneys And Diagnostics RNA, Oh My – Discussing Verici DX’s Differentiated Product Offering

Next Episode: Scrip's Five Must-Know Things - 4 December 2023

Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies (:35), the agency’s policy for using background music in direct-to-consumer advertising (7:27), and the FDA’s new incoming principal deputy commissioner (13:44).

More On These Topics From The Pink Sheet

CAR-T Malignancy Reports Could Temper Excitement For Use Beyond Oncology: https://pink.citeline.com/PS149420/CAR-T-Malignancy-Reports-Could-Temper-Excitement-For-Use-Beyond-Oncology

Background Music During Risk Segment Of Rx Drug Ads: FDA Explains Its Policy: https://pink.citeline.com/PS149411/Background-Music-During-Risk-Segment-Of-Rx-Drug-Ads-FDA-Explains-Its-Policy

US FDA Chief Scientist Bumpus Will Become Principal Deputy Commissioner: https://pink.citeline.com/PS149428/US-FDA-Chief-Scientist-Bumpus-Will-Become-Principal-Deputy-Commissioner